

Supplementary Table 1. Demographics, time from symptom onset to swabbing and cycle threshold values of diagnostic and study swabs for comparing nasopharyngeal (NP), mid-turbinate (MT) and oropharyngeal (OP) swabs

Age	Sex	Symptoms Onset to Study Swabs (Days)	Symptom Onset to Diagnostic Swab (Days)	Diagnostic Swab Site	Diagnostic Swab Ct		Study NP Swab Ct		Study MT Swab Ct		Study OP Swab Ct	
					Envelope	RdRp	Envelope	RdRp	Envelope	RdRp	Envelope	RdRp
44	M	9	4	NP	N/A	24.15	30.25	32.55	32.36	36.53	26.53	30.03
79	M	11	7	Nasal	25.17	28.51	27.88	30.45	33.09	35.38	0	N/A-Positive
29	F	15	10	NP	N/A	28.16	24.89	28.26	32.56	35.38	31.08	35.2
37	M	11	6	Nasal	27.44	31.24	24.83	27.74	32.45	34.77	31.36	33.43
28	M	8	4	NP	N/A	23.16	31.84	37.2	30.21	33.64	28.89	32.14
38	F	5	0	Nasal	26.32	30.04	19.48	21.89	29.43	31.87	34.04	38.43
41	M	10	6	NP	21.21	24.38	22.84	26.89	28.67	31.77	20.28	24.25
33	F	6	2	Nasal	16.39	19.93	28.89	31.73	29.3	31.62	32.22	34.89
61	F	8	3	Nasal	12.31	15.15	28.51	30.68	28.86	31.36	30.13	32.01
52	M	9	6	Nasal	20.56	24.35	29.34	32.36	28.29	31.32	30.39	33.75
41	F	9	5	NP	N/A	21.09	30.37	33.52	28.34	30.94	0	0
40	F	19	15	Nasal	13.24	16.74	26.95	30.05	27.04	30.77	35.82	N/A
29	M	9	4	Nasal	13.84	18.21	20.81	23.85	27.59	30.46	23.38	27.11
45	M	7	4	Nasal	21.79	25.41	27.79	30.97	27.34	30.41	29.87	32.73
18	M	7	3	NP	21.34	24.89	25.45	29.13	26.24	29.85	26.33	29.84
57	M	9	5	Nasal	20.92	24.34	22.59	25.95	26.5	29.84	23.57	27.22
46	M	6	3	Nasal	21.18	24.36	21.36	24.53	26.31	29.56	27.68	30.87
42	M	10	4	NP	N/A	24.15	27.3	30.64	25.29	28.82	23.94	27.72
59	M	10	6	Nasal	17.66	21.26	25.6	27.86	25.26	27.88	28.85	31.27
37	M	8	4	NP	N/A	25.87	0	0	22.74	26.31	0	0
39	F	11	9	Nasal	23.47	27.43	26.25	30.09	23.46	26.09	0	0
13	F	11	7	NP	19.5	22.5	25.44	27.92	22.53	25.94	34.64	36.24
62	F	4	1	Nasal	26.2	30.93	15.44	18.66	18.36	21.75	26.67	29.92
48	F	13	12	Nasal	27.03	30.08	0	0	34.42	1	0	0
60	M	19	15	NP	30.49	34.1	33.64	35.77	0	0	26.2	29.49
34	F	7	3	NP	N/A	27.94	29.75	34.92	0	0	30.56	34.84
48	F	23	21	Nasal	33.18	36.9	31	34.18	0	0	27.4	30.13
35	F	10	5	Nasal	29.39	32.71	30.31	32.64	0	0	26.53	30.22
69	M	12	8	Nasal	18.58	22.09	26.91	30.2	0	0	40.68	N/A
43	M	17	11	NP	N/A	30.06	0	0	0	0	0	0
11	M	7	3	NP	25.91	29.25	0	0	0	0	31.98	34.89
55	M	7	2	NP	33.32	37.94	0	0	0	0	0	0
39	F	12	7	Nasal	32.39	34.72	0	0	0	0	0	0
39	F	16	13	Nasal	30.55	33.27	0	0	0	0	0	0
56	M	5	0	Nasal	34.41	35.91	0	0	0	0	0	0
46	F	18	13	Nasal	28.64	32.59	0	0	0	0	0	0

All patients were in the community (not hospitalized) and were tested using the Alberta ProVLab lab-developed triplex RT-PCR targeting the Envelope and RNA-dependent RNA polymerase (RdRp) SARS-CoV-2 genes with a MS2 phage control was used for all samples. Age is at the time of the study swab. N/A=not available; Ct=cycle threshold value